Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05224089 · ClinicalTrials.gov registry record · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
A Phase 4 study of Bowel Disease, sponsored by Hartford Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT05224089: Recruiting Phase 4 study of Bowel Disease, sponsored by Hartford Hospital.
NCT05224089 is a Phase 4 study of Bowel Disease that is actively recruiting participants, run by Hartford Hospital. The registered enrollment target is 114 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05224089, a Phase 4 study of Bowel Disease, is actively recruiting participants, sponsored by Hartford Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a single center, prospective triple blinded randomized controlled study, comparing the use of liposomal bupivacaine (Exparel) to regular bupivacaine with adjuncts in bilateral mid-abdominal transverse abdominis plane (TAP) blocks for patients undergoing laparoscopic colectomy procedures.
Primary Outcome
To compare the highest (worst) pain reported for the period of 48-72 hours post-surgery.
Conditions Studied
Interventions
- DRUG Liposomal Bupivicaine/Bupivacaine Admixture
- DRUG Bupivacaine HCL
Study Locations (1)
Connecticut
- Hartford Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2026-02 |
| Phase | Phase 4 |
What NCT05224089 shows while recruiting
NCT05224089 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Bowel Disease appearing as the primary indexed condition, and to 2 interventions - of which Liposomal Bupivicaine/Bupivacaine Admixture is the first listed.
NCT05224089 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05224089 about?
NCT05224089 is a clinical study titled "Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy". This study will be a single center, prospective triple blinded randomized controlled study, comparing the use of liposomal bupivacaine (Exparel) to regular bupivacaine with adjuncts in bilateral mid-abdominal transverse abdominis plane (TAP) blocks for patients undergoing laparoscopic colectomy proc...
What is the current status of trial NCT05224089?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2022-04-27. Estimated completion is 2026-02.
What conditions does trial NCT05224089 study?
This clinical trial studies the following conditions: Bowel Disease.
What interventions are being tested in trial NCT05224089?
The interventions under investigation include: Liposomal Bupivicaine/Bupivacaine Admixture (DRUG), Bupivacaine HCL (DRUG).
Who is sponsoring clinical trial NCT05224089?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05224089 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05224089's enrollment target sits among peer trials
114 720th of 2000 higher than 1,279 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05389332 · 114 participants · NA
A Mobile Health Intervention Among Hispanics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI